Shares of Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.07 and traded as high as $0.0940. Mateon Therapeutics shares last traded at $0.0918, with a volume of 25,576 shares traded.
Mateon Therapeutics Stock Up 2.5%
The stock has a fifty day moving average price of $0.09 and a two-hundred day moving average price of $0.07. The company has a market cap of $8.28 million, a price-to-earnings ratio of -4.59 and a beta of 1.33.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
See Also
- Five stocks we like better than Mateon Therapeutics
- Canadian Penny Stocks: Can They Make You Rich?
- Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500
- Growth Stocks: What They Are, What They Are Not
- Forget the Chips: 4 Industrial Plays for the AI Rebound
- How to Calculate Inflation Rate
- MongoDB Could Hit Record Highs—But You’ll Need to Move Fast
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
